MorphoSys US, Inc.
MORDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Zanubrutinib
Mantle Cell Lymphoma
MOR202
Membranous Nephropathy
MOR103
Multiple Sclerosis
MOR00208
Contiguous Stage II Small Lymphocytic Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Zanubrutinib | Phase 2 | Mantle Cell Lymphoma | - | - |
MOR202 | Phase 2 | Membranous Nephropathy | - | - |
MOR103 | Phase 2 | Multiple Sclerosis | - | - |
MOR00208 | Phase 2 | Contiguous Stage II Small Lymphocytic Lymphoma | - | - |
Frequently asked questions
What is in MorphoSys US, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in MorphoSys US, Inc.'s (MOR) pipeline across Phase 2. Its lead program is Zanubrutinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MorphoSys US, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MorphoSys US, Inc. (MOR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MOR biotech catalysts?→
Add MOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MorphoSys US, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.